AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial
- Cocktail halved risk of developing serious illness or death
- Company has filed for emergency-use clearance in the U.S.
This article is for subscribers only.
AstraZeneca Plc’s antibody cocktail was effective at preventing mild or moderate Covid-19 infections from worsening in a study that bolsters the drugmaker’s ambitions for the product.
The cocktail halved the risk of severe illness or death compared with a placebo in 822 participants who had been symptomatic for a week or less and weren’t hospitalized, Astra said in a statement Monday.